Determine the Genetic Element on Human Chromosome 9 That Increases Risk for Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$180,000
Active Dates
September 01, 2020 - August 31, 2023
Grant ID
G2020254
Goals
Human genetic studies show glaucoma is caused by a combination of genetic risk factors. However, few specific changes have been determined. This is severely hampering our ability to identify those at risk of developing glaucoma and developing new treatments. In this study we aim to determine the specific genetic element in a genomic region that shows one of the strongest associations with glaucoma.
Summary
The aim of this research is to use mouse models to understand the mechanisms by which a region of the human genome increases risk for glaucoma. Multiple studies have shown that genetic variations in a region on human chromosome 9, containing a number of genes including CDKN2A, CDKN2B and CDKN2B-AS increase risk for glaucoma but the primary reasons behind this are not clear. In the first aim, we will use state-of-the-art genomic methods to identify and better characterize the genetic elements that are present in this region. To do this, we will use mouse models that develop high intraocular pressure. In the second aim, we will create a mouse model that allows us to remove the CDKN2B-AS gene. Unlike many genes, this gene does not code for a protein, but functions to control the expression of other protein-coding genes (such as CDKN2B). With this new mouse strain, we will be able to very precisely remove the CDKN2B-AS gene without disturbing the architecture of the surrounding genes. This work will lay the foundation to understand why the CDKN2B-AS locus modifies risk for glaucoma.
Related Grants
National Glaucoma Research
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dan Stamer, PhD
Current Organization
Duke University School of Medicine
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dan Stamer, PhD
Current Organization
Duke University School of Medicine
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
National Glaucoma Research
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear